Risk factors for progressive multifocal leukoencephalopathy identified in natalizumab-treated patients

被引：0
|
作者：
机构：
来源：
Nature Reviews Neurology | 2012年 / 8卷 / 7期
关键词：
D O I：
10.1038/nrneurol.2012.122
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：358 / 358
相关论文
共 50 条
  • [31] Predicting Risk of Progressive Multifocal Leukoencephalopathy from Natalizumab
    Ropper, Allan H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20): : 1938 - 1939
  • [32] Contribution of natalizumab treatment duration, prior immunosuppressant use, and anti-JC virus antibody status to the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients
    Bloomgren, G.
    Richman, S.
    Hotermans, C.
    Subramanyam, M.
    Goelz, S.
    Natarajan, A.
    Lee, S.
    Plavina, T.
    Scanlon, J.
    Sandrock, A.
    Bozic, C.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S451 - S452
  • [33] Cerebrospinal Fluid Proteomics Signature of Progressive Multifocal Leukoencelophathy in Natalizumab-Treated MS Patients
    Faigle, Wolfgang
    Jelcic, Ilijas
    Roschitzki, Bernd
    Martin, Roland
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 275 (1-2) : 181 - 181
  • [34] Brief report - Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
    Langer-Gould, A
    Atlas, SW
    Green, AJ
    Bollen, AW
    Pelletier, D
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04): : 375 - 381
  • [35] Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review
    Vivekanandan, Govinathan
    Abubacker, Ansha P.
    Myneni, Revathi
    Chawla, Harsh, V
    Iqbal, Aimen
    Grewal, Amit
    Ndakotsu, Andrew
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [36] Review of progressive multifocal leukoencephalopathy and natalizumab
    Aksamit, Allen J.
    NEUROLOGIST, 2006, 12 (06) : 293 - 298
  • [37] Risk stratification for progressive multifocal leukoencephalopathy in multiple sclerosis patients using natalizumab
    Sandrock, A.
    Hotermans, C.
    Richman, S.
    Natarajan, A.
    Lee, S.
    Plavina, T.
    Bloomgren, G.
    Subramanyam, M.
    Bozic, C.
    JOURNAL OF NEUROLOGY, 2011, 258 : 23 - 23
  • [38] Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
    Kraemer, J.
    Tenberge, J. -G.
    Kleiter, I.
    Gaissmaier, W.
    Ruck, T.
    Heesen, C.
    Meuth, S. G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 380 - 381
  • [39] Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
    Kraemer, Julia
    Tenberge, Jan-Gerd
    Kleiter, Ingo
    Gaissmaier, Wolfgang
    Ruck, Tobias
    Heesen, Christoph
    Meuth, Sven G.
    PLOS ONE, 2017, 12 (04):
  • [40] Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis
    Alvarez-Cermeño, JC
    Masjuan, J
    Villar, LM
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1744 - 1745
12345